Pairwise analysis of outcomes at 18-month IL-5 treatment with overall reductions at 6 months, 12 months and 18 months of treatment
| 12 months pretreatment | 6 months treatment | 12 months treatment | 18 months treatment | |
| Exacerbation—hospitalisation | 132 | 10 p<0.001 (CI 0.04 to 0.16) | 24 p=0.004 (CI 0.08 to 0.61) | 33 p=0.036 (CI 0.17 to 0.94) |
| Exacerbations—non-inpatient | 109 | 12 p=0.02 (CI 0.06 to 0.79) | 19 p=0.027 (CI 0.11 to 0.88) | 24 p=0.014 (CI 0.12 to 0.79) |
| GP visits | 637 | 89 p<0.001 (CI 0.12 to 0.26) | 160 p<0.001 (CI 0.23 to 0.40) | 210 p<0.001 (CI 0.31 to 0.52) |
Exacerbation = increase in asthma symptoms requiring oral corticosteroid treatment/increase in maintenance oral corticosteroid dose for management
Exacerbations—hospitalisations = total number of recorded exacerbations requiring inpatient hospital treatment of at least 1 day.
Exacerbation—non-inpatient = total number recorded exacerbations requiring specialist respiratory review but not requiring inpatient management.
GP visits = total number of respiratory-associated GP visits during this period.
12 months pretreatment = total number of events recorded for 12 months prior to starting IL-5 treatment.
6 months treatment = total number of events recorded in the 6 months following commencement of IL-5 inhibitor treatment. 12 months treatment = total number of events recorded in the 12 months following commencement of IL-5 inhibitor treatment. 18 months treatment = total number of events recorded in the 18 months following commencement of IL-5 inhibitor treatment.
P value = probability significance measure. CI = CI for the associated p value.